A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with relapsed/refractory anaplastic large cell lymphoma (ALCL) .
Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
DRUG: TQ-B3101 capsule
Overall response rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR) according to Lugano response criteria., Baseline up to 18 months
Progression free survival (PFS) within 2-year, PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause., Baseline up to 24 months|Overall survival (OS) within 2-year, OS was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., Baseline up to 24 months
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with relapsed/refractory anaplastic large cell lymphoma (ALCL) .